Patents by Inventor Jeffrey C. Kern

Jeffrey C. Kern has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • UREA OREXIN RECEPTOR AGONISTS
    Publication number: 20240101555
    Abstract: The present invention is directed to urea compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: December 14, 2021
    Publication date: March 28, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Kira A. Armacost, Maria Irina Chiriac, Danielle M. Hurzy, Jeffrey C. Kern, Jian Liu, Peter J. Manley, Philippe Nantermet, Vanessa L. Rada, Michael T. Rudd, Craig A. Stump
  • Phosphonate linkers and their use to facilitate cellular retention of compounds
    Patent number: 11883500
    Abstract: Phosphonate linkers and their use for delivering compounds with passive cell permeability into a cell wherein the phosphonate group facilitates cellular retention of the compound are described.
    Type: Grant
    Filed: December 2, 2022
    Date of Patent: January 30, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Robert M. Garbaccio, Jeffrey C. Kern, James J. Mulhearn, Philip E. Brandish
  • MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS
    Publication number: 20230391795
    Abstract: The present invention is directed to macrocyclic urea compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    Type: Application
    Filed: October 28, 2021
    Publication date: December 7, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Kira A. Armacost, Maria Irina Chiriac, Danielle M. Hurzy, Jeffrey C. Kern, Jian Liu, Peter J. Manley, Vanessa L. Rada, Michael T. Rudd, Craig A. Stump, Zhe Wu, Dong Xiao
  • PHOSPHONATE LINKERS AND THEIR USE TO FACILIATE CELLULAR RETENTION OF COMPOUNDS
    Publication number: 20230147502
    Abstract: Phosphonate linkers and their use for delivering compounds with passive cell permeability into a cell wherein the phosphonate group facilitates cellular retention of the compound are described.
    Type: Application
    Filed: December 2, 2022
    Publication date: May 11, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Robert M. Garbaccio, Jeffrey C. Kern, James J. Mulhearn, Philip E. Brandish
  • Phosphonate linkers and their use to facilitate cellular retention of compounds
    Patent number: 11554172
    Abstract: Phosphonate linkers and their use for delivering compounds with passive cell permeability into a cell wherein the phosphonate group facilitates cellular retention of the compound are described.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: January 17, 2023
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Robert M. Garbaccio, Jeffrey C. Kern, James J. Mulhearn, Philip E. Brandish
  • PHOSPHONATE LINKERS AND THEIR USE TO FACILITATE CELLULAR RETENTION OF COMPOUNDS
    Publication number: 20210015930
    Abstract: Phosphonate linkers and their use for delivering compounds with passive cell permeability into a cell wherein the phosphonate group facilitates cellular retention of the compound are described.
    Type: Application
    Filed: September 24, 2020
    Publication date: January 21, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Robert M. Garbaccio, Jeffrey C. Kern, James J. Mulhearn, Philip E. Brandish
  • Phosphonate linkers and their use to facilitate cellular retention of compounds
    Patent number: 10869929
    Abstract: Phosphonate linkers and their use for delivering compounds with passive cell permeability into a cell wherein the phosphonate group facilitates cellular retention of the compound are described.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: December 22, 2020
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Robert M. Garbaccio, Jeffrey C. Kern, James J. Mulhearn, Philip E. Brandish
  • PHOSPONATE LINKERS AND THEIR USE TO FACILITATE CELLULAR RETENTION OF COMPOUNDS
    Publication number: 20190030171
    Abstract: Phosphonate linkers and their use for delivering compounds with passive cell permeability into a cell wherein the phosphonate group facilitates cellular retention of the compound are described.
    Type: Application
    Filed: January 24, 2017
    Publication date: January 31, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Robert M. Garbaccio, Jeffrey C. Kern, James J. Mulhearn, Philip E. Brandish
  • Imidazopyridin-2-one derivatives
    Patent number: 9315518
    Abstract: The present invention is directed to imidazopyridin-2-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: April 19, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Hannah D. Fiji, Michael J. Kelly, III, Jeffrey C. Kern, Mark E. Layton, Joseph E. Pero, Alexander J. Reif, Michael A. Rossi
  • IMIDAZOPYRIDIN-2-ONE DERIVATIVES
    Publication number: 20140350002
    Abstract: The present invention is directed to imidazopyridin-2-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
    Type: Application
    Filed: June 14, 2012
    Publication date: November 27, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Hannah D. Fiji, Michael J. Kelly, III, Jeffrey C. Kern, Mark E. Layton, Joseph E. Pero, Alexander J. Reif, Michael A. Rossi